Public Health Service Act: Compliance Risks for Healthcare Entities

Organizations subject to federal program compliance obligations through HHS grants must meet ongoing reporting, audit, and programmatic requirements as a condition of continued funding.

Section 319 of the Public Health Service Act is the statutory authority that empowers the HHS Secretary to declare a public health emergency and mobilize federal resources.

Section 319, at 42 U.S.C. § 247d, authorizes that declaration when any of the following conditions exist:

• A disease or disorder presents a significant threat
• A significant outbreak exists
• A bioterrorist attack or similar public health threat has occurred

A Section 319 declaration is effective for 90 days and may be renewed as long as emergency conditions persist. It authorizes emergency grants, contracts, awards, and investigations.

A Section 319 declaration is effective for 90 days and may be renewed as long as emergency conditions persist. It authorizes emergency grants, contracts, awards, and investigations.

A Section 319 declaration can support emergency grants, contracts, investigations, and certain reporting or administrative flexibilities. It does not automatically waive Medicare, Medicaid, provider-condition, or payment rules. Those waivers often require separate authority, such as Social Security Act § 1135, and agency-specific guidance.

Organizations should confirm which waiver or flexibility actually applies before modifying operations.

Key compliance questions include:

• Does the declaration affect HRSA grant timelines or 340B program flexibility?
• What documentation must providers maintain during the emergency period?
• Does a PREP Act declaration also apply for medical countermeasure liability purposes?

Section 361, at 42 U.S.C. § 264, authorizes the federal government to prevent the spread of communicable diseases from foreign countries into the United States and from one state or territory to another. The CDC administers this authority through 42 C.F.R. Parts 70 and 71. Measures available under Section 361 include inspection, apprehension, detention, and conditional release of individuals reasonably believed to be carrying a designated communicable disease.

Federal quarantine authority intersects with constitutional due process protections. Federal Section 361 authority and state police power can overlap. Because that relationship has produced litigation, jurisdiction-specific analysis is required. State and local public health agencies retain substantial independent authority that may impose obligations beyond the federal framework.

The PREP Act is part of the federal public health emergency framework. It can provide liability immunity for covered countermeasures when a qualifying declaration applies. The core liability protection provision is 42 U.S.C. § 247d-6d, which governs immunity for covered persons in connection with the administration or use of covered countermeasures.

Coverage depends on whether all of the following conditions are met:

• A qualifying PREP Act declaration is in effect
• The entity qualifies as a covered person under the declaration
• The product is a covered countermeasure as defined in the declaration
• Documentation and administration requirements are met

Organizations involved in medical countermeasures should review the applicable PREP Act declaration before assuming liability protection applies. This includes manufacturers, distributors, pharmacies, hospitals, prescribers, and administering entities. The healthcare regulatory implications of a gap in PREP Act coverage can be significant.

The 340B Drug Pricing Program is a federal program that requires certain drug manufacturers to sell outpatient drugs to eligible health care organizations at significantly reduced prices. Established at 42 U.S.C. § 256b, it requires Medicaid-participating manufacturers to provide covered outpatient drugs at or below a statutory ceiling price. According to HRSA program data, more than 50,000 covered entity site locations have participated in the 340B program. This makes it one of the largest federal drug discount programs in the United States.

Covered entities that may qualify include:

• Federally qualified health centers (FQHCs)
• Ryan White HIV/AIDS clinics
• Disproportionate share hospitals (DSH)
• HRSA-designated grantees and look-alike organizations

HRSA audits both covered entities and manufacturers. Adverse findings can result in repayment obligations, corrective action plan requirements, program removal, or referral for false claims act enforcement. 340B rebate models, contract pharmacy restrictions, and manufacturer distribution limits remain active litigation and agency-review issues. Covered entities and manufacturers should confirm current HRSA guidance and applicable court orders before changing payment or distribution practices.

• Federally qualified health centers (FQHCs)
• Ryan White HIV/AIDS clinics
• Disproportionate share hospitals (DSH)
• HRSA-designated grantees and look-alike organizations

Covered entities must maintain compliance across several key areas:

HRSA audits both covered entities and manufacturers. Adverse findings can result in repayment obligations, corrective action plan requirements, program removal, or referral for false claims act enforcement. 340B rebate models, contract pharmacy restrictions, and manufacturer distribution limits remain active litigation and agency-review issues. Covered entities and manufacturers should confirm current HRSA guidance and applicable court orders before changing payment or distribution practices.

Section 330 of the PHS Act, at 42 U.S.C. § 254b, establishes the federal grant program for community health centers serving medically underserved populations. Section 330 grantees must meet HRSA requirements across four core areas:

• Service delivery in health professional shortage areas or medically underserved areas
• Governance by a patient-majority board of directors
• Comprehensive primary care regardless of ability to pay
• Ongoing reporting, cost allowability, and grant condition compliance

Grant disallowance findings, HRSA corrective action plan demands, and cost-allowability disputes require prompt legal review. Response deadlines under Section 330 are typically short.

A biologics license application is the regulatory submission required under Section 351 of the Public Health Service Act before any biological product may be sold in the United States.

Section 351, at 42 U.S.C. § 262, requires that each BLA demonstrate the following:

• Safety, purity, and potency of the product
• Adequate manufacturing facilities and processes
• Proper labeling, including proper name, manufacturer, license number, and expiration date
• Sufficient preclinical and clinical data to support approval

FDA regulations governing biologics are found at 21 C.F.R. Parts 600 through 680. The framework applies to therapeutic proteins and monoclonal antibodies, vaccines and blood products, cell and gene therapies, and allergenics and tissue products.

Section 351(k) establishes the abbreviated approval pathway for biosimilar products. Applicants may rely on existing safety and efficacy data from the reference biologic while demonstrating biosimilarity. The higher standard of interchangeability requires additional evidence supporting substitution under the statutory standard, which may allow pharmacy-level substitution subject to state law. The biosimilar framework has expanded significantly since the first U.S. .iosimilar approval in 2015, and FDA approval data should be checked for the current number of approved products.

• Postmarket pharmacovigilance and adverse event reporting
• BLA supplement requirements for manufacturing changes
• FDA inspection readiness and current Good Manufacturing Practice compliance
• Adverse event reporting under 21 C.F.R. Part 600

Organizations subject to Section 351 should maintain quality systems, regulatory affairs procedures, inspection-readiness files, and postmarket reporting controls. Enforcement actions can include warning letters, license suspension or revocation, product recall, civil monetary penalties, and criminal referral.

FDA regulatory compliance review should address both premarket approval obligations and postmarket surveillance responsibilities. Pharmaceutical regulatory compliance programs should be reviewed whenever a manufacturing change, labeling revision, or new safety signal arises.

Agency actions by HHS, HRSA, FDA, and CDC under the PHS Act are generally subject to review under the Administrative Procedure Act. Courts apply the APA's arbitrary and capricious standard to agency rules and informal decisions. Procedural challenges may also be available where the agency failed to follow required notice-and-comment rulemaking procedures.

The 340B ADR process provides a formal mechanism for covered entities and manufacturers to contest HRSA determinations. ADR filings and responses are subject to strict procedural requirements and deadlines. Administrative law counsel can evaluate the available options and protect organizational rights. The review should account for the APA, HHS adjudication procedures, and federal health program enforcement rules.

Contact a qualified administrative law attorney promptly if your organization has received an agency notice, audit finding, or enforcement communication under any provision of the Public Health Service Act. Organizations should also confirm applicable state and local public health requirements. State law may interact with federal PHS Act programs differently by location.